BIOCRYST PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended March 31, 2026, two of the directors and officers of the Company adopted, modified orterminated the “Rule 10b5-1 trading arrangements” (as such term is defined in Item 408(a) of Regulation S-K) as set forth in the table below.
| Name (Title) | Action | Date of Action | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|
| Ron Dullinger,Chief Commercial Officer | Adoption | March 2, 2026 | Until February 26, 2027, or such earlier date upon which all transactions are completed or the plan is terminated | (1) |
| Jon Stonehouse, Member of the Board of Directors | Adoption | March 3, 2026 | Until December 31, 2027, or such earlier date upon which all transactions are completed or the plan is terminated | (2) |
(1) This trading plan provides for the sale of up to (i)151,868 shares of common stock underlying stock options and (ii)64,738 shares of common stock underlying restricted stock units, net of shares withheld to cover taxes.
(2) This trading plan provides for the sale of up to 800,000 shares of common stock underlying stock options expiring in 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.